JP2007523650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523650A5 JP2007523650A5 JP2006553317A JP2006553317A JP2007523650A5 JP 2007523650 A5 JP2007523650 A5 JP 2007523650A5 JP 2006553317 A JP2006553317 A JP 2006553317A JP 2006553317 A JP2006553317 A JP 2006553317A JP 2007523650 A5 JP2007523650 A5 JP 2007523650A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- cell
- metastatic
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 40
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 31
- 210000004881 tumor cell Anatomy 0.000 claims description 31
- 230000001394 metastastic effect Effects 0.000 claims description 29
- 206010006187 Breast cancer Diseases 0.000 claims description 28
- 208000026310 Breast neoplasm Diseases 0.000 claims description 28
- 108010044426 integrins Proteins 0.000 claims description 23
- 102000006495 integrins Human genes 0.000 claims description 23
- 206010027476 Metastases Diseases 0.000 claims description 20
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 14
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 12
- 230000009401 metastasis Effects 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 51
- 108091033319 polynucleotide Proteins 0.000 claims 24
- 102000040430 polynucleotide Human genes 0.000 claims 24
- 239000002157 polynucleotide Substances 0.000 claims 24
- 241000124008 Mammalia Species 0.000 claims 23
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 21
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 230000000683 nonmetastatic effect Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 231100000433 cytotoxic Toxicity 0.000 claims 6
- 230000001472 cytotoxic effect Effects 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 230000036470 plasma concentration Effects 0.000 claims 5
- 230000002001 anti-metastasis Effects 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000005641 Adenomyosis Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 206010066476 Haematological malignancy Diseases 0.000 claims 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000005476 astroblastoma Diseases 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 201000007455 central nervous system cancer Diseases 0.000 claims 3
- 201000009274 endometriosis of uterus Diseases 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 206010027191 meningioma Diseases 0.000 claims 3
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 201000002511 pituitary cancer Diseases 0.000 claims 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 201000007954 uterine fibroid Diseases 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000008827 biological function Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 208000016018 endometrial polyp Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000004091 panning Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000007790 solid phase Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 206010046811 uterine polyp Diseases 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 101150023971 Cd48 gene Proteins 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 238000000441 X-ray spectroscopy Methods 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 239000003131 biological toxin Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000010399 physical interaction Effects 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 230000005522 programmed cell death Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 239000000941 radioactive substance Substances 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 description 10
- 102000008946 Fibrinogen Human genes 0.000 description 9
- 108010049003 Fibrinogen Proteins 0.000 description 9
- 229940012952 fibrinogen Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 108010064365 glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine Proteins 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 230000005012 migration Effects 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 108010031318 Vitronectin Proteins 0.000 description 4
- 102100035140 Vitronectin Human genes 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000007646 directional migration Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 208000013210 hematogenous Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- ZRVZOBGMZWVJOS-VMXHOPILSA-N (2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN ZRVZOBGMZWVJOS-VMXHOPILSA-N 0.000 description 1
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000150534 El Moro Canyon orthohantavirus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000004712 cancer cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54480704P | 2004-02-13 | 2004-02-13 | |
| US62672604P | 2004-11-10 | 2004-11-10 | |
| US11/056,825 US7271245B2 (en) | 2004-02-13 | 2005-02-11 | Methods and compositions for inhibition of metastasis |
| PCT/US2005/004612 WO2005091805A2 (en) | 2004-02-13 | 2005-02-14 | Methods and compositions for inhibition of metastasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523650A JP2007523650A (ja) | 2007-08-23 |
| JP2007523650A5 true JP2007523650A5 (enExample) | 2008-04-03 |
Family
ID=35056641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553317A Withdrawn JP2007523650A (ja) | 2004-02-13 | 2005-02-14 | 転移を阻害するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7271245B2 (enExample) |
| EP (1) | EP1725111A4 (enExample) |
| JP (1) | JP2007523650A (enExample) |
| CA (1) | CA2559480A1 (enExample) |
| WO (1) | WO2005091805A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2490280A1 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2854576A1 (en) * | 2005-07-18 | 2007-01-25 | Haichun Huang | Human anti-b7rp1 neutralizing antibodies |
| US20100104572A1 (en) * | 2006-11-02 | 2010-04-29 | Sylvie Luria | Methods for screening for therapeutic molecules and use of the molecules therefrom |
| US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
| US20110118446A1 (en) * | 2007-09-28 | 2011-05-19 | The General Hospital Corporation | Methods and compositions for antibody production |
| WO2009070753A2 (en) * | 2007-11-28 | 2009-06-04 | The Scripps Research Institute | Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject |
| BRPI0821417A2 (pt) * | 2007-12-26 | 2015-06-16 | Biotest Ag | Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo |
| EP2268306A2 (en) * | 2008-03-14 | 2011-01-05 | The Board Of Trustees Of The University Of Illinois | Therapeutic cancer antigens |
| WO2010017083A1 (en) * | 2008-08-04 | 2010-02-11 | Wayne State University | Methods of treating cancer with cd11b antibodies |
| WO2014028862A1 (en) | 2012-08-17 | 2014-02-20 | Cornell University | Use of dna in circulating exosomes as a diagnostic marker for metastasic disease |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| JP2016519081A (ja) | 2013-03-14 | 2016-06-30 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体 |
| WO2015048413A1 (en) * | 2013-09-30 | 2015-04-02 | X-Body Biosciences, Inc. | Antigen receptor screening assay |
| EP3125907A4 (en) | 2014-04-01 | 2017-11-29 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
| WO2016057702A2 (en) * | 2014-10-07 | 2016-04-14 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| WO2019241847A1 (en) * | 2018-06-22 | 2019-12-26 | Baker Heart and Diabetes Institute | A therapeutic gpiib/iiia binding-protein drug conjugate and use thereof |
| US20220169746A1 (en) * | 2019-02-26 | 2022-06-02 | The University Of Vermont And State Agricultural College | Antibodies to neoantigens and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| DE69322860T2 (de) * | 1992-04-03 | 1999-07-01 | Genentech, Inc., South San Francisco, Calif. | Antikörper gegen alpha v beta 3 integrin |
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| KR0119887B1 (ko) * | 1994-06-08 | 1997-10-30 | 김광호 | 반도체 메모리장치의 웨이퍼 번-인 테스트 회로 |
| US6596850B1 (en) * | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
| WO1998046265A1 (en) * | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Methods for using antagonistic anti-avb3 integrin antibodies |
| AU6954398A (en) * | 1997-04-11 | 1998-11-11 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
| US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| EP1135688A2 (en) * | 1998-12-04 | 2001-09-26 | Novartis AG | Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| US6531580B1 (en) * | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| US20020025510A1 (en) * | 2000-07-26 | 2002-02-28 | Strongin Alex Y. | Screening methods based on superactivated alpha V beta 3 integrin |
| US20030129188A1 (en) * | 2001-10-22 | 2003-07-10 | The Scripps Research Institute | Integrin targeting compounds |
| CA2478239A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
-
2005
- 2005-02-11 US US11/056,825 patent/US7271245B2/en not_active Expired - Fee Related
- 2005-02-14 JP JP2006553317A patent/JP2007523650A/ja not_active Withdrawn
- 2005-02-14 WO PCT/US2005/004612 patent/WO2005091805A2/en not_active Ceased
- 2005-02-14 EP EP05760713A patent/EP1725111A4/en not_active Withdrawn
- 2005-02-14 CA CA002559480A patent/CA2559480A1/en not_active Abandoned
-
2007
- 2007-08-01 US US11/832,570 patent/US20090117096A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523650A5 (enExample) | ||
| JP7442591B2 (ja) | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 | |
| USRE44681E1 (en) | Compositions and methods for inhibiting growth of SMAD4-deficient cancers | |
| Munesue et al. | The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones | |
| JP4918403B2 (ja) | 転移および転移がもたらす骨格関連現象を調節する方法 | |
| AU2017279835A1 (en) | Identification and enrichment of cell subpopulations | |
| CN101287841A (zh) | 抗－αvβ6抗体及其用途 | |
| JP2009528525A (ja) | ネトリン−１活性を用いた抗癌化合物のスクリーニング | |
| JP2013522167A (ja) | ｕＰＡＲ結合剤及びその使用方法 | |
| US8188051B2 (en) | Metadherin polypeptides, encoding nucleic acids and methods of use | |
| EP3123173B1 (en) | Compositions for suppressing cancer by inhibition of tmcc3 | |
| EP1907420B1 (en) | Plexin d1 as a target for tumor diagnosis and therapy | |
| CN102539734A (zh) | 核仁素辅助的癌症诊断与治疗方法 | |
| JP2007523092A (ja) | 新脈管形成阻害のための方法および組成物 | |
| US20100055089A1 (en) | Methods for Inhibition of Lymphangiogenesis and Tumor Metastasis | |
| US7642341B2 (en) | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer | |
| US20090252738A1 (en) | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix | |
| WO2011005377A2 (en) | Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease | |
| CN113087772A (zh) | 一种rhamm拮抗多肽及其衍生物与应用 | |
| KR20170138465A (ko) | Igf-1r 항체 및 암의 진단을 위한 그의 용도 | |
| KR20180073670A (ko) | 암 줄기 세포를 표적화하여 공격성 암을 치료하기 위한 항체 | |
| CN113214360A (zh) | 一种rhamm拮抗多肽及其衍生物与应用 | |
| JP2008545750A (ja) | Ｅｐｈｂ３モジュレーターを使用する、癌を処置、診断または検出するための方法 | |
| Wong | Genetic and mechanistic determinants of prostate cancer progression and metastasis | |
| JP2007308466A (ja) | サイトカイン媒介疾患の治療方法 |